Quick Answer
MoonLake Immunotherapeutics reported Diluted EPS of $3.53 per share (loss) for fiscal year 2025.
MoonLake Immunotherapeutics Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.53 | -86.8% |
| 2024 | -$1.89 | -158.9% |
| 2023 | -$0.73 | +57.1% |
| 2022 | -$1.70 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.10 | -96.4% | -26.4% |
| June 30, 2025 | -$0.87 | -123.1% | -38.1% |
| March 31, 2025 | -$0.63 | -186.4% | -12.5% |
| September 30, 2024 | -$0.56 | -211.1% | -43.6% |
| June 30, 2024 | -$0.39 | -69.6% | -77.3% |
| March 31, 2024 | -$0.22 | +4.3% | -22.2% |
| September 30, 2023 | -$0.18 | +33.3% | +21.7% |
| June 30, 2023 | -$0.23 | +32.4% | +0.0% |
- MoonLake Immunotherapeutics showed a decrease of -86.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, MoonLake Immunotherapeutics’s diluted eps has declined by 107.6% (from $1.70 per share (loss) to $3.53 per share (loss)).
- The most recent figure is from MoonLake Immunotherapeutics’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: